Exicure has struck a deal to offload its GPC-100 program, pocketing roughly $4.8 million in cash from buyer GPCRT. The transaction covers a bundle of intellectual property, assets, and licensing rights tied to the burixafor therapeutic candidate.
The sale arrives at a pivotal moment for small-cap biotech firms facing mounting pressure to streamline pipelines and secure nondilutive funding. Partnering or divesting non-core assets has become a survival strategy across the sector.
Under the terms, GPCRT will pay 6.5 billion Korean won in three installments. A deposit has already landed in Exicure’s accounts, with an interim payment due by November 16, 2026, followed by a final settlement when the deal closes.
The agreement, signed November 4 and effective November 30, remains contingent on standard closing conditions and regulatory consents. Once finalized, GPCRT assumes certain forward-looking obligations connected to the program. Exicure and its subsidiary will retain other existing liabilities.
Neither company detailed which specific commitments transfer to GPCRT. However, the structure suggests a clean break for Exicure on the GPC-100 front, freeing internal resources for other priorities.
Burixafor, also known as GPC-100, has been explored as a stem cell mobilization agent. The asset’s commercial potential hinges on further development, which now falls to GPCRT.
Wall Street will likely watch how Exicure deploys the incoming cash. For a company of its size, $4.8 million can meaningfully extend the runway or seed new research initiatives. The closing timeline remains uncertain, though both parties have signaled intent to complete the transfer once all conditions clear.
